Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug
Despite weak evidence that Aduhelm helps patients, the drug, a monthly infusion priced at $56,000 per year, was approved this week. An independent committee of scientists that advised the Food and Drug Administration on Biogen’s controversial Alzheimer’s drug has resigned in strong protest against the agency’s approval. “This might be the F.D.A.’s worst approval decision … Read more